Show simple item record

dc.contributor.authorCortinovis, Diego
dc.contributor.authorMalapelle, Umberto
dc.contributor.authorPagni, Fabio
dc.contributor.authorRusso, Alessandro
dc.contributor.authorBanna, Giuseppe Luigi
dc.contributor.authorSala, Elisa
dc.contributor.authorRolfo, Christian
dc.date.accessioned2021-08-30T17:12:16Z
dc.date.available2021-08-30T17:12:16Z
dc.identifier.urihttp://hdl.handle.net/10713/16501
dc.description.abstractObjective: This review aims to summarize the possibilities of recently discovered molecular diagnostic techniques in lung cancer, by evaluating their impact on diagnosis, monitoring, and prognosis in oligometastatic disease. Background: Oligometastatic non-small cell lung cancer (OM-NSCLC) is currently defined based on morphological rather than biological features. Major advances in the detection of molecular biomarkers in cell-free tumoral DNA and the models of oncogene addiction make as feasible an early diagnosis and guide the therapeutic decision-making progress to improve the prognosis. Methods: This narrative review EXAMINES current approaches of diagnosis, monitoring, and prognosis of OM-NSCLC and describes the fast-evolving therapeutic scenario of this disease. We provide an overview of the powerful capability of liquid biopsy techniques applied to blood and fluid and we focus on the technological advancement of circulant biomolecular factors in OM NSCLC pathology, starting from apparently simpler models such as oncogene addicted tumors to evaluate themselves in the light of treatment with immune-checkpoint inhibitors. Conclusions: A better understanding of spatial and temporal evolution of oligometastatic diseases would contribute to a more accurate diagnosis and tailored treatment. Data from prospective clinical trials in the early stage of disease, coupled with knowledge of genetic characteristics of lung tumors, are warranted. These efforts would lead to improving the possibility to eradicate the residual disease in these low burden tumoral settings, thus enhancing the definitive cure perspectives.en_US
dc.description.urihttps://doi.org/10.21037/tlcr-20-1067en_US
dc.language.isoenen_US
dc.publisherPioneer Bioscience Publishing Companyen_US
dc.relation.ispartofTranslational Lung Cancer Researchen_US
dc.rights2021 Translational Lung Cancer Research. All rights reserved.en_US
dc.subjectCirculating biomarkersen_US
dc.subjectlung canceren_US
dc.subjectoligometastaticen_US
dc.titleDiagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature reviewen_US
dc.typeArticleen_US
dc.identifier.doi10.21037/tlcr-20-1067
dc.identifier.pmid34430374
dc.source.volume10
dc.source.issue7
dc.source.beginpage3385
dc.source.endpage3400
dc.source.countryChina


This item appears in the following Collection(s)

Show simple item record